Xenetic Biosciences Commences Patient Enrollment in Phase 2 Study Evaluating XBIO-101 in Conjunction with Progestin Therapy for the Treatment of Endometrial Cancer
Xenetic Biosciences Receives Program Update from Partner Shire’s Phase 1/2 Study Evaluating SHP656 in Development as a Long-acting Treatment for Hemophilia A
Xenetic Biosciences Reports 2017 First Quarter Financial Results and Provides Business Update
Xenetic Biosciences to Host 2017 First Quarter Update Conference Call
Xenetic Biosciences Presents Case Study of PolyXen™ Platform Technology at the 13th Annual Protein Engineering Summit (PEGS) Boston
Xenetic Biosciences’ PolyXen™ Platform Technology Accepted for Poster Presentation at the 13th Annual Protein Engineering Summit (PEGS) Boston
Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer
Xenetic Biosciences Reports 2016 Year End Financial Results and Provides Business Update
Xenetic Biosciences to Ring Nasdaq Stock Market Opening Bell on March 30, 2017
